Market capitalization | $30.94m |
Enterprise Value | $34.02m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.72 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-27.01m |
Free Cash Flow (TTM) Free Cash Flow | $-26.59m |
EPS (TTM) EPS | $-38.96 |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
2 Analysts have issued a ERYTech Pharma SA Sponsored ADR forecast:
2 Analysts have issued a ERYTech Pharma SA Sponsored ADR forecast:
Dec '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.79 -0.79 |
88%
88%
|
|
EBITDA | -26 -26 |
12%
12%
|
EBIT (Operating Income) EBIT | -27 -27 |
25%
25%
|
Net Profit | -25 -25 |
8,090%
8,090%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.
Head office | France |
CEO | Thibaut Fayet |
Employees | 68 |
Founded | 2004 |
Website | www.phaxiam.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.